1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
In first-line metastatic breast cancer, the bevacizumab-taxane to progression or toxicity, is
currently the standard treatment. In patients expressing hormone receptors, it was shown that
hormone therapy administered in maintenance after induction chemotherapy, could have a
benefit regarding the progression-free survival. The investigators make the hypothesis that
there would be interest to discontinue treatment with taxane after 4 months, and to begin
hormone therapy while continuing maintenance bevacizumab.
Exemestane was chosen because it has been shown potentially active in patients who progressed
after letrozole, anastrozole or tamoxifen.